David Shen, PhD

SVP, Biologics Research and CMC at NGM Biopharmaceuticals

David Shen is Sr. VP of NGM Biopharmaceuticals a leading
expert with more than 20 years of experience in the antibody
and therapeutic protein field, and has a proven record of
advancing pipelines from discovery to proof-of-concept in
clinical stage to registration. Dr. Shen joined NGM in 2013
and was most recently Vice President, Global Head of
Biologics Development at TEVA Pharmaceuticals and
managed the innovative biologics, biobetters and biosimilars
portfolio across therapeutic areas. During his tenure, several
biologics/biosimilars were successfully approved, including
TBO-Filgrastim by FDA and Lipegfilgrastim by EMA. Prior
to TEVA, Dr. Shen was Executive Director, Biologics
Research and GlycoFi at Merck where he oversaw overall
biologics pipeline from discovery to preclinical development.
His professional career started at Amgen where he held
positions of increasing responsibility, including site-head for
the Protein Sciences Department in San Francisco, and was
critical in advancing more than eight antibody drug candidates
from research to clinical development and regulatory
approval, including evolucumab (anti-PCSK9), romosozumab
(anti-sclerostin) and denosumab (anti-RANKL). In addition,
he has developed the mammalian full IgG display technology
that is now widely used by the antibody field. Dr. Shen
graduated from East China University of Science and
Technology and received a Ph.D. from University of Toronto.
He completed post-doctoral training at the Whitehead
Institute for Biomedical Research.